melatonin has been researched along with Movement Disorders in 14 studies
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin levels were significantly higher in third ventricle than in the plasma, whereas there was no difference between plasma and lateral ventricle levels." | 5.36 | Melatonin is released in the third ventricle in humans. A study in movement disorders. ( Brun, J; Claustrat, B; Harthé, C; Leston, J; Mertens, P; Mottolese, C; Sindou, M, 2010) |
| "Melatonin has been shown to improve sleep in several conditions." | 2.73 | Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. ( Carvalhedo de Bruin, PF; de Bruin, VM; de Lourdes Seabra, M; Lopes, LA; Magalhães, MC; Medeiros, CA, 2007) |
| "Melatonin was prescribed to 52 children, all but one were extended-release preparations." | 1.91 | Sleep related rhythmic movement disorder: phenotypic characteristics and treatment response in a paediatric cohort. ( Benny, A; Hewertson, V; Hill, CM; Joels, H; Joseph, B; Marshall, A; Piantino, C; Postigo, B; Sharpe, A, 2023) |
| "Melatonin (10mg/kg) was given once daily at the same time." | 1.42 | Melatonin ameliorates oxidative damage induced by maternal lead exposure in rat pups. ( Bazrgar, M; Elahdadi Salmani, M; Goudarzi, I; Lashkarbolouki, T, 2015) |
| "Melatonin levels were significantly higher in third ventricle than in the plasma, whereas there was no difference between plasma and lateral ventricle levels." | 1.36 | Melatonin is released in the third ventricle in humans. A study in movement disorders. ( Brun, J; Claustrat, B; Harthé, C; Leston, J; Mertens, P; Mottolese, C; Sindou, M, 2010) |
| "Stage and duration of Parkinson's disease did not correlate with the amount of secreted melatonin." | 1.29 | Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. ( Auff, E; Doppelbauer, A; Fertl, E; Waldhauser, F, 1993) |
| "Treatment with haloperidol resulted in significantly more severe movement disorder in pinealectomized rats than in unoperated control rats." | 1.28 | Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats. ( Fisher, H; Sandyk, R, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Joels, H | 1 |
| Benny, A | 1 |
| Sharpe, A | 1 |
| Postigo, B | 1 |
| Joseph, B | 1 |
| Piantino, C | 1 |
| Marshall, A | 1 |
| Hewertson, V | 1 |
| Hill, CM | 1 |
| Ueda, Y | 1 |
| Masuda, T | 1 |
| Ishida, A | 1 |
| Misumi, S | 1 |
| Shimizu, Y | 1 |
| Jung, CG | 1 |
| Hida, H | 1 |
| Lerner, PP | 1 |
| Miodownik, C | 2 |
| Lerner, V | 2 |
| Bazrgar, M | 1 |
| Goudarzi, I | 1 |
| Lashkarbolouki, T | 1 |
| Elahdadi Salmani, M | 1 |
| Leston, J | 1 |
| Harthé, C | 1 |
| Brun, J | 1 |
| Mottolese, C | 1 |
| Mertens, P | 1 |
| Sindou, M | 1 |
| Claustrat, B | 1 |
| Castro, F | 1 |
| Carrizo, E | 1 |
| Prieto de Rincón, D | 1 |
| Rincón, CA | 1 |
| Asián, T | 1 |
| Medina-Leendertz, S | 1 |
| Bonilla, E | 1 |
| Medeiros, CA | 1 |
| Carvalhedo de Bruin, PF | 1 |
| Lopes, LA | 1 |
| Magalhães, MC | 1 |
| de Lourdes Seabra, M | 1 |
| de Bruin, VM | 1 |
| Fertl, E | 1 |
| Auff, E | 1 |
| Doppelbauer, A | 1 |
| Waldhauser, F | 1 |
| Sandyk, R | 2 |
| Fisher, H | 1 |
| Erlich, SS | 1 |
| Apuzzo, ML | 1 |
| Carman, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for melatonin and Movement Disorders
| Article | Year |
|---|---|
Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; alpha-Tocopherol; Amantadine; Anticonvuls | 2015 |
Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Fatty Acids, Omega-3; Ginkgo biloba; Humans; Levetira | 2011 |
MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders.
Topics: Affect; Animals; Corpus Striatum; Dopamine; Drug Synergism; Humans; Melatonin; Movement Disorders; M | 1990 |
The pineal gland: anatomy, physiology, and clinical significance.
Topics: Analgesia; Animals; Brain Neoplasms; Circadian Rhythm; Depression; Electroencephalography; Humans; H | 1985 |
3 trials available for melatonin and Movement Disorders
| Article | Year |
|---|---|
Effectiveness of melatonin in tardive dyskinesia.
Topics: Adult; Antioxidants; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Melatonin; Mid | 2011 |
Melatonin-controlled release - neurim pharmaceuticals. Circadin, melatonin-prolonged release, melatonin-sustained release.
Topics: Administration, Oral; Age Factors; Delayed-Action Preparations; Drugs, Investigational; Dyskinesia, | 2003 |
Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antioxidants; Double-Blind Method; Female; Humans; Male; Melatoni | 2007 |
7 other studies available for melatonin and Movement Disorders
| Article | Year |
|---|---|
Sleep related rhythmic movement disorder: phenotypic characteristics and treatment response in a paediatric cohort.
Topics: Autism Spectrum Disorder; Child; Female; Humans; Male; Melatonin; Movement Disorders; Parasomnias; R | 2023 |
Enhanced electrical responsiveness in the cerebral cortex with oral melatonin administration after a small hemorrhage near the internal capsule in rats.
Topics: Administration, Oral; Animals; Antioxidants; Cells, Cultured; Cerebral Cortex; Cerebral Hemorrhage; | 2014 |
Melatonin ameliorates oxidative damage induced by maternal lead exposure in rat pups.
Topics: Animals; Cerebellum; Female; Glutathione Peroxidase; Lead; Lipid Peroxidation; Maternal Exposure; Me | 2015 |
Melatonin is released in the third ventricle in humans. A study in movement disorders.
Topics: Adult; Age Factors; Aged; Female; Humans; Lateral Ventricles; Male; Melatonin; Middle Aged; Movement | 2010 |
Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa.
Topics: Aged; Circadian Rhythm; Female; Humans; Levodopa; Male; Melatonin; Middle Aged; Movement Disorders; | 1993 |
Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats.
Topics: Animals; Antipsychotic Agents; Haloperidol; Male; Melatonin; Movement Disorders; Pineal Gland; Rats; | 1989 |
Pigment and kinesia.
Topics: Adult; Age Factors; Aged; Black People; Humans; Melatonin; Middle Aged; Movement Disorders; Pigmenta | 1973 |